ArticleJournal of Cancer2025
Pan-cancer analysis reveals SGO1 as a potential cancer prognostic and immunological biomarker.
Article in Journal of Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shugoshin 1 (SGO1) is primarily known for its critical functions in chromosome segregation during cell division, protecting cohesin complexes and ensuring accurate mitotic processes. Previous studies have reported SGO1's regulatory roles in isolated cancer types, but its pan-cancer significance and underlying mechanisms remain undefined. This study systematically investigates SGO1 in 33 cancer types, integrating multi-omics analyses and functional validation to reveal its role as a pan-cancer biomarker and therapeutic target. Using TCGA, GEPIA2, and HPA databases, we found SGO1 was significantly overexpressed in 19 cancer types compared to normal tissues. High SGO1 expression correlated with poorer overall survival (OS) and disease-free survival (DFS) in more than 10 cancers, validated by Kaplan-Meier analysis. Genomic analysis revealed frequent SGO1 mutations and DNA methylation dysregulation, while immune profiling showed associations with immune cell infiltration (B cells, CD8+ T cells) and PD-1/PD-L1 checkpoint genes. Protein-protein interaction and enrichment analyses uncovered BUB1 as a key co-expressed gene, suggesting a role in spindle checkpoint regulation. Functional assays in breast cancer cell line MDA-MB-231 and lung cancer cell line A549 showed SGO1 knockdown inhibited proliferation, migration, and invasion, with xenograft models confirming reduced tumor growth. Our findings establish SGO1 as a novel pan-cancer biomarker, linking its expression to tumor progression, immune evasion, and genomic instability. This study bridges bioinformatics with functional validation, offering new mechanistic insights and therapeutic avenues for SGO1-driven cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.